450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

Background: Diabetic Cardiomyopathy (DbCM) is a form of Stage B heart failure (HF). Concentrations of N-terminal pro-B type natriuretic peptide (NT-proBNP) may predict risk for HF progression in persons with DbCM. The ARISE-HF study (NCT04083339) is evaluating efficacy of AT-001, a highly selective...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 72; no. Supplement_1; p. 1
Main Authors BUTLER, JAVED, DEL PRATO, STEFANO, EZEKOWITZ, JUSTIN, IBRAHIM, NASRIEN E., LAM, CAROLYN S., PERFETTI, RICCARDO, ROSENSTOCK, JULIO, WILSON TANG, W.H., URBINATI, ALESSIA, ZANNAD, FAIEZ, JANUZZI, JAMES L.
Format Journal Article
LanguageEnglish
Published New York American Diabetes Association 20.06.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Diabetic Cardiomyopathy (DbCM) is a form of Stage B heart failure (HF). Concentrations of N-terminal pro-B type natriuretic peptide (NT-proBNP) may predict risk for HF progression in persons with DbCM. The ARISE-HF study (NCT04083339) is evaluating efficacy of AT-001, a highly selective aldose reductase inhibitor (AT-001) to improve exercise tolerance in affected patients. The aim of this analysis was to assess association between baseline NT-proBNP and cardiac status in type 2 diabetes participants with DbCM. Methods: Impaired exercise tolerance and baseline characteristics were evaluated in 679 patients with DbCM as a function of NT-proBNP at enrollment. Results: Median NT-proBNP in the overall study population was 71 ng/L (IQR 35-133). Baseline characteristics were similar across NT-proBNP concentrations, however, participants with higher NT-proBNP had higher left atrial volume (p<0.001) and higher right ventricular systolic pressure (p=0.04) on baseline echocardiogram. Higher NT-proBNP concentrations were associated with reduced physical activity reflected in lower PASE Score and a worse functional capacity reflected in lower peak VO2 (p<0.001) (Table 1). Conclusion: Among patients with DbCM, elevated NT-proBNP is associated with echocardiographic abnormalities and worse cardiac functional capacity and inversely associated with activity.
AbstractList Background: Diabetic Cardiomyopathy (DbCM) is a form of Stage B heart failure (HF). Concentrations of N-terminal pro-B type natriuretic peptide (NT-proBNP) may predict risk for HF progression in persons with DbCM. The ARISE-HF study (NCT04083339) is evaluating efficacy of AT-001, a highly selective aldose reductase inhibitor (AT-001) to improve exercise tolerance in affected patients. The aim of this analysis was to assess association between baseline NT-proBNP and cardiac status in type 2 diabetes participants with DbCM. Methods: Impaired exercise tolerance and baseline characteristics were evaluated in 679 patients with DbCM as a function of NT-proBNP at enrollment. Results: Median NT-proBNP in the overall study population was 71 ng/L (IQR 35-133). Baseline characteristics were similar across NT-proBNP concentrations, however, participants with higher NT-proBNP had higher left atrial volume (p<0.001) and higher right ventricular systolic pressure (p=0.04) on baseline echocardiogram. Higher NT-proBNP concentrations were associated with reduced physical activity reflected in lower PASE Score and a worse functional capacity reflected in lower peak VO2 (p<0.001) (Table 1). Conclusion: Among patients with DbCM, elevated NT-proBNP is associated with echocardiographic abnormalities and worse cardiac functional capacity and inversely associated with activity.
Background: Diabetic Cardiomyopathy (DbCM) is a form of Stage B heart failure (HF). Concentrations of N-terminal pro-B type natriuretic peptide (NT-proBNP) may predict risk for HF progression in persons with DbCM. The ARISE-HF study (NCT04083339) is evaluating efficacy of AT-001, a highly selective aldose reductase inhibitor (AT-001) to improve exercise tolerance in affected patients. The aim of this analysis was to assess association between baseline NT-proBNP and cardiac status in type 2 diabetes participants with DbCM. Methods: Impaired exercise tolerance and baseline characteristics were evaluated in 679 patients with DbCM as a function of NT-proBNP at enrollment. Results: Median NT-proBNP in the overall study population was 71 ng/L (IQR 35-133). Baseline characteristics were similar across NT-proBNP concentrations, however, participants with higher NT-proBNP had higher left atrial volume (p<0.001) and higher right ventricular systolic pressure (p=0.04) on baseline echocardiogram. Higher NT-proBNP concentrations were associated with reduced physical activity reflected in lower PASE Score and a worse functional capacity reflected in lower peak VO2 (p<0.001) (Table 1). Conclusion: Among patients with DbCM, elevated NT-proBNP is associated with echocardiographic abnormalities and worse cardiac functional capacity and inversely associated with activity.
Author URBINATI, ALESSIA
IBRAHIM, NASRIEN E.
PERFETTI, RICCARDO
EZEKOWITZ, JUSTIN
JANUZZI, JAMES L.
ROSENSTOCK, JULIO
ZANNAD, FAIEZ
LAM, CAROLYN S.
DEL PRATO, STEFANO
WILSON TANG, W.H.
BUTLER, JAVED
Author_xml – sequence: 1
  givenname: JAVED
  surname: BUTLER
  fullname: BUTLER, JAVED
– sequence: 2
  givenname: STEFANO
  surname: DEL PRATO
  fullname: DEL PRATO, STEFANO
– sequence: 3
  givenname: JUSTIN
  surname: EZEKOWITZ
  fullname: EZEKOWITZ, JUSTIN
– sequence: 4
  givenname: NASRIEN E.
  surname: IBRAHIM
  fullname: IBRAHIM, NASRIEN E.
– sequence: 5
  givenname: CAROLYN S.
  surname: LAM
  fullname: LAM, CAROLYN S.
– sequence: 6
  givenname: RICCARDO
  surname: PERFETTI
  fullname: PERFETTI, RICCARDO
– sequence: 7
  givenname: JULIO
  surname: ROSENSTOCK
  fullname: ROSENSTOCK, JULIO
– sequence: 8
  givenname: W.H.
  surname: WILSON TANG
  fullname: WILSON TANG, W.H.
– sequence: 9
  givenname: ALESSIA
  surname: URBINATI
  fullname: URBINATI, ALESSIA
– sequence: 10
  givenname: FAIEZ
  surname: ZANNAD
  fullname: ZANNAD, FAIEZ
– sequence: 11
  givenname: JAMES L.
  surname: JANUZZI
  fullname: JANUZZI, JAMES L.
BookMark eNotkLtOwzAYhS1UJEph4QkssSEZ7DjOha1XWqkqFWRgi_6kf1RXbRxsd8iGeAaekCehF3SGs3w60vmuSac2NRJyJ_hjIGX8tCoCyULF2fKCdEUqUyaD-KNDupyLgIk4ja_ItXMbznl0SJd8n-BnumAZ2p2uYUuX1rABzdoG6QK81XuLXpd0iY3XK6RDU5dYewtem9pRXdORhuKEDMGutNm1pgG_bn-_fgbgcKtrpCPwQCtrdtSvkfbfZu9jNp3QzGrY3pDLCrYOb_-7R7LJOBtO2fz1ZTbsz1kZSc5UCkkKMopEEgJPC4UVcgBZhKs0VIiFgkhGoVKh4DIouYpjKTCOqyJSKJJE9sj9ebax5nOPzucbs7eHwy4PkjCVkeABP1APZ6q0xjmLVd5YvQPb5oLnR8X5UXF-sJYv5R9iFW-T
ContentType Journal Article
Copyright Copyright American Diabetes Association Jun 2023
Copyright_xml – notice: Copyright American Diabetes Association Jun 2023
DBID AAYXX
CITATION
K9.
NAPCQ
DOI 10.2337/db23-450-P
DatabaseName CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1939-327X
ExternalDocumentID 10_2337_db23_450_P
Genre Conference Proceeding
GroupedDBID ---
.55
.XZ
08P
0R~
18M
29F
2WC
354
4.4
53G
5GY
5RE
5RS
5VS
6PF
8R4
8R5
AAQQT
AAWTL
AAYEP
AAYXX
ABOCM
ACGFO
ACGOD
ACPRK
ADBBV
AEGXH
AENEX
AERZD
AFHIN
AHMBA
AIAGR
AIZAD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BES
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EDB
EMOBN
EX3
F5P
FRP
GX1
H13
HZ~
IAO
IEA
IHR
INH
INR
IOF
IPO
K2M
KQ8
L7B
M5~
O5R
O5S
O9-
OHH
OK1
OVD
P2P
PCD
Q2X
RHF
RHI
RPM
SJN
SV3
TDI
TEORI
TR2
VVN
W8F
WH7
WOQ
WOW
X7M
YFH
YHG
YOC
ZY1
~KM
K9.
NAPCQ
ID FETCH-LOGICAL-c630-59a89a366184a09b5efe0aa3b4d945eeb5a63645541032c057731e77fb65e1883
ISSN 0012-1797
IngestDate Thu Oct 10 20:45:25 EDT 2024
Fri Dec 06 01:56:18 EST 2024
IsPeerReviewed true
IsScholarly true
Issue Supplement_1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c630-59a89a366184a09b5efe0aa3b4d945eeb5a63645541032c057731e77fb65e1883
PQID 2849361020
PQPubID 34443
ParticipantIDs proquest_journals_2849361020
crossref_primary_10_2337_db23_450_P
PublicationCentury 2000
PublicationDate 2023-06-20
PublicationDateYYYYMMDD 2023-06-20
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-20
  day: 20
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationTitle Diabetes (New York, N.Y.)
PublicationYear 2023
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
SSID ssj0006060
Score 2.4724267
Snippet Background: Diabetic Cardiomyopathy (DbCM) is a form of Stage B heart failure (HF). Concentrations of N-terminal pro-B type natriuretic peptide (NT-proBNP) may...
SourceID proquest
crossref
SourceType Aggregation Database
StartPage 1
SubjectTerms Aldehyde reductase
Blood pressure
Cardiomyopathy
Congestive heart failure
Diabetes
Diabetes mellitus (non-insulin dependent)
Echocardiography
Exercise
Peptides
Physical activity
Physical fitness
Physical training
Population studies
Ventricle
Title 450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial
URI https://www.proquest.com/docview/2849361020
Volume 72
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEuiKcoFLQS3KIta3v94ua0jmIgDyUuVL1YXnsjVSouKsmhnBC_gSO_jl_CzPqRTemhcLEiy7NOPF88j_1mhpDXgANuh8JhBcTITFi8ZMFScgber7TDQMErEAuFxxNvdCTeHbvHvd4vg7W0Xsn94tu1dSX_o1U4B3rFKtl_0Gy3KJyAz6BfOIKG4XgjHQuXsxnG9BOW1qSWM2T-s0Efw0skIl-crnWZYn-G7JUSZ9RVNR-z45DXnBi45EBTUz9fnuOU4suWBSEGua5ZVwCQVW6Uo8yTRcxGw36KP9T0cQ-NdO7VQT9G4mGA_ZjnNYo-xh3x-DD-ALCI0qnOy6bxMJpMO7f_JH4__ZSkJ1rqaJEm3UZSMphHo2Ss7xMt5kk86cf7ZkrDxvESzObma9qysW-qb76mfduAox55qvOnmXWdIbAd3UqglLC41sXG3LVb_FesYMdNhKgIpTOUzUA2m90it7HNomhzQY2dh9CvLnBqvmzd_BZl32zuu-3ubFt77cKk98m9JvagUQ2kB6SnqofkzrhhVzwiP_Rab-kGTVSjiSKaqIEm2qCJbqOJnla0RRPdRtPv7z9bHFHEEUUcUcARbXFENY4ek3QYpwcj1szoYIXncOaGeRDmjodjg3IeSlctFc9zR4oyFK5S0s093Oh2BTZuLCA48B1L-f5Seq6ygsB5Qnaq80o9JbRQRQBiRcGXcHVRBsqWQs_G9oMSrOAuedU-yexL3Ykl-1tXu2SvfchZ80_9moELFjoQJ9j82Y0WeU7ubmC5R3ZWF2v1AnzPlXypIfAHWIV8qQ
link.rule.ids 314,780,784,27924,27925
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=450-P%3A+N-Terminal+Pro-B+Type+Natriuretic+Peptide+Concentrations+in+Diabetic+Cardiomyopathy%E2%80%94Baseline+Data+from+the+ARISE-HF+Trial&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=BUTLER%2C+JAVED&rft.au=DEL+PRATO%2C+STEFANO&rft.au=EZEKOWITZ%2C+JUSTIN&rft.au=IBRAHIM%2C+NASRIEN+E.&rft.date=2023-06-20&rft.issn=0012-1797&rft.volume=72&rft.issue=Supplement_1&rft_id=info:doi/10.2337%2Fdb23-450-P&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db23_450_P
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon